Targeting the intrinsically disordered architectural High Mobility Group A (HMGA) oncoproteins in breast cancer: learning from the past to design future strategies

References

• Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene. 2001;277:63–81.
   PubMed Web of Science ®Google Scholar
• Reeves R, Beckerbauer L. HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta. 2001;1519:13–29.
   PubMed Web of Science ®Google Scholar
• Sgarra R, Rustighi A, Tessari MA, et al. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett. 2004;574:1–8.
   PubMed Web of Science ®Google Scholar
• Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat Rev Cancer. 2007;7:899–910.
   PubMed Web of Science ®Google Scholar
• Manfioletti G, Giancotti V, Bandiera A, et al. cDNA cloning of the HMGI-C phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes. Nucleic Acids Res. 1991;19:6793–6797.
   PubMed Web of Science ®Google Scholar
• Pfannkuche K, Summer H, Li O, et al. The high mobility group protein HMGA2: a co-regulator of chromatin structure and pluripotency in stem cells? Stem Cell Rev Rep. 2009;5:224–230.
   PubMed Web of Science ®Google Scholar
• Munshi N, Agalioti T, Lomvardas S, et al. Coordination of a transcriptional switch by HMGI(Y) acetylation. Science. 2001;293:1133–1136.
   PubMed Web of Science ®Google Scholar
• Reeves R. High mobility group (HMG) proteins: modulators of chromatin structure and DNA repair in mammalian cells. DNA Repair (Amst). 2015;36:122–136.
   PubMed Web of Science ®Google Scholar
• Thomae AW, Baltin J, Pich D, et al. Different roles of the human Orc6 protein in the replication initiation process. Cell Mol Life Sci. 2011;68:3741–3756.
   PubMed Web of Science ®Google Scholar
• Thomae AW, Pich D, Brocher J, et al. Interaction between HMGA1a and the origin recognition complex creates site-specific replication origins. Proc Natl Acad Sci USA. 2008;105:1692–1697.
   PubMed Web of Science ®Google Scholar
• Senigagliesi B, Penzo C, Severino LU, et al. The High Mobility Group A1 (HMGA1) chromatin architectural factor modulates nuclear stiffness in breast cancer cells. Int J Mol Sci. 2019;20:2733.
   Web of Science ®Google Scholar
• Manabe T, Katayama T, Sato N, et al. Induced HMGA1a expression causes aberrant splicing of Presenilin-2 pre-mRNA in sporadic Alzheimer’s disease. Cell Death Differ. 2003;10:698–708.
   PubMed Web of Science ®Google Scholar
• Mantovani F, Covaceuszach S, Rustighi A, et al. NF-kappaB mediated transcriptional activation is enhanced by the architectural factor HMGI-C. Nucleic Acids Res. 1998;26:1433–1439.
   PubMed Web of Science ®Google Scholar
• Palmieri D, Valentino T, De Martino I, et al. PIT1 upregulation by HMGA proteins has a role in pituitary tumorigenesis. Endocr Relat Cancer. 2012;19:123–135.
   PubMed Web of Science ®Google Scholar
• Sgarra R, Pegoraro S, Ros G, et al. High Mobility Group A (HMGA) proteins: molecular instigators of breast cancer onset and progression. Biochim Biophys Acta Rev Cancer. 2018;1869:216–229.
   PubMed Web of Science ®Google Scholar
• Sgarra R, Pegoraro S, D’Angelo D, et al. High Mobility Group A (HMGA): chromatin nodes controlled by a knotty miRNA network. Int J Mol Sci. 2020;21:717.
   Web of Science ®Google Scholar
• Lee YS, Dutta A. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 2007;21:1025–1030.
   PubMed Web of Science ®Google Scholar
• Maher JF, Nathans D. Multivalent DNA-binding properties of the HMG-1 proteins. Proc Natl Acad Sci USA. 1996;93:6716–6720.
   PubMed Web of Science ®Google Scholar
• Sgarra R, Zammitti S, Lo Sardo A, et al. HMGA molecular network: from transcriptional regulation to chromatin remodeling. Biochim Biophys Acta. 2010;1799:37–47.
   PubMed Web of Science ®Google Scholar
• Schwanbeck R, Manfioletti G, Wiśniewski JR. Architecture of high mobility group protein I-C.DNA complex and its perturbation upon phosphorylation by Cdc2 kinase. J Biol Chem. 2000;275:1793–1801.
   PubMed Web of Science ®Google Scholar
• Sgarra R, Maurizio E, Zammitti S, et al. Macroscopic differences in HMGA oncoproteins post-translational modifications: C-terminal phosphorylation of HMGA2 affects its DNA binding properties. J Proteome Res. 2009;8:2978–2989.
   PubMed Web of Science ®Google Scholar
• Maurizio E, Cravello L, Brady L, et al. Conformational role for the C-terminal tail of the intrinsically disordered high mobility group A (HMGA) chromatin factors. J Proteome Res. 2011;10:3283–3291.
   PubMed Web of Science ®Google Scholar
• Sgarra R, Tessari MA, Di Bernardo J, et al. Discovering high mobility group A molecular partners in tumour cells. Proteomics. 2005;5:1494–1506.
   PubMed Web of Science ®Google Scholar
• Sgarra R, Furlan C, Zammitti S, et al. Interaction proteomics of the HMGA chromatin architectural factors. Proteomics. 2008;8:4721–4732.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Reeves R, Beckerbauer LM. HMGA proteins as therapeutic drug targets. Prog Cell Cycle Res. 2003;5:279–286.
   PubMedGoogle Scholar
• Shah SN, Resar LMS. High mobility group A1 and cancer: potential biomarker and therapeutic target. Histol Histopathol. 2012;27:567–579.
   PubMed Web of Science ®Google Scholar
• Huso TH, Resar LMS. The high mobility group A1 molecular switch: turning on cancer - can we turn it off? Expert Opin Ther Targets. 2014;18:541–553.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.
   PubMed Web of Science ®Google Scholar
• Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321:288–300.
   PubMed Web of Science ®Google Scholar
• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–1281.
   PubMed Web of Science ®Google Scholar
• Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271–3277.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389:1134–1150.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Jovanović B, Chen X, et al. Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE. 2016;11:e0157368.
   PubMed Web of Science ®Google Scholar
• Denkert C, Liedtke C, Tutt A, et al. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389:2430–2442.
   PubMed Web of Science ®Google Scholar
• Poggio F, Bruzzone M, Ceppi M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29:1497–1508.
   PubMed Web of Science ®Google Scholar
• Robson M, Im S-A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523–533.
   PubMed Web of Science ®Google Scholar
• Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753–763.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, et al. Atezolizumab and Nab-Paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–2121.
   PubMed Web of Science ®Google Scholar
• Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–821.
   PubMed Web of Science ®Google Scholar
• Tolza C, Bejjani F, Evanno E, et al. AP-1 signaling by Fra-1 directly regulates HMGA1 oncogene transcription in triple-negative breast cancers. Mol Cancer Res. 2019;17:1999–2014.
   PubMed Web of Science ®Google Scholar
• El Ayachi I, Fatima I, Wend P, et al. The WNT10B network is associated with survival and metastases in chemoresistant triple-negative breast cancer. Cancer Res. 2019;79:982–993.
   PubMed Web of Science ®Google Scholar
• Fatima I, El-Ayachi I, Playa HC, et al. Simultaneous multi-organ metastases from chemo-resistant triple-negative breast cancer are prevented by interfering with wnT-signaling. Cancers (Basel). 2019;11:2039.
   Web of Science ®Google Scholar
• Fatima I, El-Ayachi I, Taotao L, et al. The natural compound Jatrophone interferes with Wnt/β-catenin signaling and inhibits proliferation and EMT in human triple-negative breast cancer. PLoS ONE. 2017;12:e0189864.
   PubMed Web of Science ®Google Scholar
• Thuault S, Valcourt U, Petersen M, et al. Transforming growth factor-beta employs HMGA2 to elicit epithelial-mesenchymal transition. J Cell Biol. 2006;174:175–183.
   PubMed Web of Science ®Google Scholar
• Thuault S, Tan E-J, Peinado H, et al. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J Biol Chem. 2008;283:33437–33446.
   PubMed Web of Science ®Google Scholar
• Kolliopoulos C, Lin C-Y, Heldin C-H, et al. Has2 natural antisense RNA and Hmga2 promote Has2 expression during TGFβ-induced EMT in breast cancer. Matrix Biol. 2019;80:29–45.
   PubMed Web of Science ®Google Scholar
• Medina MA, Oza G, Sharma A, et al. Triple-negative breast cancer: a review of conventional and advanced therapeutic strategies. Int J Environ Res Public Health. 2020;17:2078.
   PubMed Web of Science ®Google Scholar
• Zhang S, Mo Q, Wang X. Oncological role of HMGA2 (review). Int J Oncol. 2019;55:775–788.
   PubMed Web of Science ®Google Scholar
• Resar L, Chia L, Xian L. Lessons from the Crypt: HMGA1-Amping up Wnt for stem cells and tumor progression. Cancer Res. 2018;78:1890–1897.
   PubMed Web of Science ®Google Scholar
• Sumter TF, Xian L, Huso T, et al. The High Mobility Group A1 (HMGA1) transcriptome in cancer and development. Curr Mol Med. 2016;16:353–393.
   PubMed Web of Science ®Google Scholar
• Pegoraro S, Ros G, Piazza S, et al. HMGA1 promotes metastatic processes in basal-like breast cancer regulating EMT and stemness. Oncotarget. 2013;4:1293–1308.
   PubMed Web of Science ®Google Scholar
• Shah SN, Cope L, Poh W, et al. HMGA1: a master regulator of tumor progression in triple-negative breast cancer cells. PLoS ONE. 2013;8:e63419.
   PubMed Web of Science ®Google Scholar
• Penzo C, Arnoldo L, Pegoraro S, et al. HMGA1 modulates gene transcription sustaining a tumor signalling pathway acting on the epigenetic status of triple-negative breast cancer cells. Cancers (Basel). 2019;11:1105.
   Web of Science ®Google Scholar
• Zanin R, Pegoraro S, Ros G, et al. HMGA1 promotes breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1. J Exp Clin Cancer Res. 2019;38:313.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Duijf PHG, Mohammadi A, et al. Overexpression of HMGA2 in breast cancer promotes cell proliferation, migration, invasion and stemness. Expert Opin Ther Targets. 2020;24:255–265.
   Web of Science ®Google Scholar
• Tan E-J, Kahata K, Idås O, et al. The high mobility group A2 protein epigenetically silences the Cdh1 gene during epithelial-to-mesenchymal transition. Nucleic Acids Res. 2015;43:162–178.
   PubMed Web of Science ®Google Scholar
• Morishita A, Zaidi MR, Mitoro A, et al. HMGA2 is a driver of tumor metastasis. Cancer Res. 2013;73:4289–4299.
   PubMed Web of Science ®Google Scholar
• de Carné Trécesson S, Souazé F, Basseville A, et al. BCL-XL directly modulates RAS signalling to favour cancer cell stemness. Nat Commun. 2017;8:1123.
   PubMed Web of Science ®Google Scholar
• Guo L, Cheng X, Chen H, et al. Induction of breast cancer stem cells by M1 macrophages through Lin-28B-let-7-HMGA2 axis. Cancer Lett. 2019;452:213–225.
   PubMed Web of Science ®Google Scholar
• Frankenberger C, Rabe D, Bainer R, et al. Metastasis suppressors regulate the tumor microenvironment by blocking recruitment of prometastatic tumor-associated macrophages. Cancer Res. 2015;75:4063–4073.
   PubMed Web of Science ®Google Scholar
• Sun M, Gomes S, Chen P, et al. RKIP and HMGA2 regulate breast tumor survival and metastasis through lysyl oxidase and syndecan-2. Oncogene. 2014;33:3528–3537.
   PubMed Web of Science ®Google Scholar
• Payne SL, Fogelgren B, Hess AR, et al. Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Res. 2005;65:11429–11436.
   PubMed Web of Science ®Google Scholar
• Kirschmann DA, Seftor EA, Fong SFT, et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res. 2002;62:4478–4483.
   PubMed Web of Science ®Google Scholar
• Saatci O, Kaymak A, Raza U, et al. Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer. Nat Commun. 2020;11:2416.
   PubMed Web of Science ®Google Scholar
• Sun M, Song C-X, Huang H, et al. HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci USA. 2013;110:9920–9925.
   PubMed Web of Science ®Google Scholar
• Pentimalli F, Palmieri D, Pacelli R, et al. HMGA1 protein is a novel target of the ATM kinase. Eur J Cancer. 2008;44:2668–2679.
   PubMed Web of Science ®Google Scholar
• Pellarin I, Arnoldo L, Costantini S, et al. The architectural chromatin factor High Mobility Group A1 Enhances DNA Ligase IV activity influencing DNA Repair. PLoS ONE. 2016;11:e0164258.
   PubMed Web of Science ®Google Scholar
• Li AYJ, Boo LM, Wang S-Y, et al. Suppression of nonhomologous end joining repair by overexpression of HMGA2. Cancer Res. 2009;69:5699–5706.
   PubMed Web of Science ®Google Scholar
• Borrmann L, Schwanbeck R, Heyduk T, et al. High mobility group A2 protein and its derivatives bind a specific region of the promoter of DNA repair gene ERCC1 and modulate its activity. Nucleic Acids Res. 2003;31:6841–6851.
   PubMed Web of Science ®Google Scholar
• Summer H, Li O, Bao Q, et al. HMGA2 exhibits dRP/AP site cleavage activity and protects cancer cells from DNA-damage-induced cytotoxicity during chemotherapy. Nucleic Acids Res. 2009;37:4371–4384.
   PubMed Web of Science ®Google Scholar
• D’Angelo D, Mussnich P, Arra C, et al. Critical role of HMGA proteins in cancer cell chemoresistance. J Mol Med. 2017;95:353–360.
   PubMed Web of Science ®Google Scholar
• Méndez O, Peg V, Salvans C, et al. Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer. Clin Cancer Res. 2018;24:6367–6382.
   PubMed Web of Science ®Google Scholar
• Méndez O, Pérez J, Soberino J, et al. Clinical implications of extracellular HMGA1 in breast cancer. Int J Mol Sci. 2019;20:5950.
   Web of Science ®Google Scholar
• Lopez-Bertoni H, Lal B, Michelson N, et al. Epigenetic modulation of a miR-296-5p: HMGA1axis regulates Sox2 expression and glioblastoma stem cells. Oncogene. 2016;35:4903–4913.
   PubMed Web of Science ®Google Scholar
• Kaur H, Ali SZ, Huey L, et al. The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Lett. 2016;377:55–64.
   PubMed Web of Science ®Google Scholar
• Colamaio M, Tosti N, Puca F, et al. HMGA1 silencing reduces stemness and temozolomide resistance in glioblastoma stem cells. Expert Opin Ther Targets. 2016;20:1169–1179.
   PubMed Web of Science ®Google Scholar
• Parisi S, Piscitelli S, Passaro F, et al. HMGA proteins in stemness and differentiation of embryonic and adult stem cells. Int J Mol Sci. 2020;21:362.
   Web of Science ®Google Scholar
• Palmieri D, Valentino T, D’Angelo D, et al. HMGA proteins promote ATM expression and enhance cancer cell resistance to genotoxic agents. Oncogene. 2011;30:3024–3035.
   PubMed Web of Science ®Google Scholar
• D’Angelo D, Mussnich P, Rosa R, et al. High mobility group A1 protein expression reduces the sensitivity of colon and thyroid cancer cells to antineoplastic drugs. BMC Cancer. 2014;14:851.
   PubMed Web of Science ®Google Scholar
• Hombach-Klonisch S, Kalantari F, Medapati MR, et al. HMGA2 as a functional antagonist of PARP1 inhibitors in tumor cells. Mol Oncol. 2019;13:153–170.
   PubMed Web of Science ®Google Scholar
• Ahmed SM, Oncofetal DP. HMGA2 attenuates genotoxic damage induced by topoisomerase II target compounds through the regulation of local DNA topology. Mol Oncol. 2019;13:2062–2078.
   PubMed Web of Science ®Google Scholar
• Ohe K, Miyajima S, Abe I, et al. HMGA1a induces alternative splicing of estrogen receptor alpha in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol. 2018;182:21–26.
   PubMed Web of Science ®Google Scholar
• Chen X, Liu M, Meng F, et al. The long noncoding RNA HIF1A-AS2 facilitates cisplatin resistance in bladder cancer. J Cell Biochem. 2019;120:243–252.
   PubMed Web of Science ®Google Scholar
• Chen Y-N, Ren -C-C, Yang L, et al. MicroRNA let‑7d‑5p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1. Int J Oncol. 2019;54:1771–1784.
   PubMed Web of Science ®Google Scholar
• Baldassarre G, Belletti B, Battista S, et al. HMGA1 protein expression sensitizes cells to cisplatin-induced cell death. Oncogene. 2005;24:6809–6819.
   PubMed Web of Science ®Google Scholar
• Liau -S-S, Whang E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin Cancer Res. 2008;14:1470–1477.
   PubMed Web of Science ®Google Scholar
• Cao Y-D, Huang P-L, Sun X-C, et al. Silencing of high mobility group A1 enhances gemcitabine chemosensitivity of lung adenocarcinoma cells. Chin Med J. 2011;124:1061–1068.
   PubMed Web of Science ®Google Scholar
• Quintavalle C, Burmeister K, Piscuoglio S, et al. High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy. Mol Carcinog. 2017;56:2146–2157.
   PubMed Web of Science ®Google Scholar
• Wang C-Q. MiR-195 reverses 5-FU resistance through targeting HMGA1 in gastric cancer cells. Eur Rev Med Pharmacol Sci. 2019;23:3771–3778.
   PubMed Web of Science ®Google Scholar
• Kim DK, Seo EJ, Choi EJ, et al. Crucial role of HMGA1 in the self-renewal and drug resistance of ovarian cancer stem cells. Exp Mol Med. 2016;48:e255.
   PubMed Web of Science ®Google Scholar
• Ohe K, Miyajima S, Tanaka T, et al. HMGA1 A induces alternative splicing of the estrogen receptor-αlpha gene by trapping U1 snRNP to an upstream pseudo-5ʹ splice site. Front Mol Biosci. 2018;5:52.
   PubMed Web of Science ®Google Scholar
• Kao C-Y, Yang P-M, Wu M-H, et al. Heat shock protein 90 is involved in the regulation of HMGA2-driven growth and epithelial-to-mesenchymal transition of colorectal cancer cells. PeerJ. 2016;4:e1683.
   PubMed Web of Science ®Google Scholar
• Jiang W, Finniss S, Cazacu S, et al. Repurposing phenformin for the targeting of glioma stem cells and the treatment of glioblastoma. Oncotarget. 2016;7:56456–56470.
   PubMedGoogle Scholar
• Thanasupawat T, Natarajan S, Rommel A, et al. Dovitinib enhances temozolomide efficacy in glioblastoma cells. Mol Oncol. 2017;11:1078–1098.
   PubMed Web of Science ®Google Scholar
• Yang M-Y, Chen M-T, Huang P-I, et al. Nuclear localization signal-enhanced polyurethane-short branch polyethylenimine-mediated delivery of let-7a inhibited cancer stem-like properties by targeting the 3ʹ-UTR of HMGA2 in anaplastic astrocytoma. Cell Transplant. 2015;24:1431–1450.
   PubMed Web of Science ®Google Scholar
• Boo LM, Lin HH, Chung V, et al. High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation. Cancer Res. 2005;65:6622–6630.
   PubMed Web of Science ®Google Scholar
• Xu X, Wang Y, Deng H, et al. HMGA2 enhances 5-fluorouracil chemoresistance in colorectal cancer via the Dvl2/Wnt pathway. Oncotarget. 2018;9:9963–9974.
   PubMedGoogle Scholar
• Ma S, Fu T, Zhao S, et al. MicroRNA-34a-5p suppresses tumorigenesis and progression of glioma and potentiates Temozolomide-induced cytotoxicity for glioma cells by targeting HMGA2. Eur J Pharmacol. 2019;852:42–50.
   PubMed Web of Science ®Google Scholar
• Eivazy P, Atyabi F, Jadidi-Niaragh F, et al. The impact of the codelivery of drug-siRNA by trimethyl chitosan nanoparticles on the efficacy of chemotherapy for metastatic breast cancer cell line (MDA-MB-231). Artif Cells Nanomed Biotechnol. 2017;45:889–896.
   PubMed Web of Science ®Google Scholar
• Siahmansouri H, Somi MH, Babaloo Z, et al. Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line. J Pharm Pharmacol. 2016;68:1119–1130.
   PubMed Web of Science ®Google Scholar
• Ahmed SM, Ramani PD, Wong SQR, et al. The chromatin structuring protein HMGA2 influences human subtelomere stability and cancer chemosensitivity. PLoS ONE. 2019;14:e0215696.
   PubMed Web of Science ®Google Scholar
• Xiao G, Wang X, Yu Y. CXCR4/Let-7a axis regulates metastasis and chemoresistance of pancreatic cancer cells through targeting HMGA2. Cell Physiol Biochem. 2017;43:840–851.
   PubMedGoogle Scholar
• Dangi-Garimella S, Sahai V, Ebine K, et al. Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression. PLoS ONE. 2013;8:e64566.
   PubMed Web of Science ®Google Scholar
• Nana AW, Chin Y-T, Lin C-Y, et al. Tetrac downregulates β-catenin and HMGA2 to promote the effect of resveratrol in colon cancer. Endocr Relat Cancer. 2018;25:279–293.
   PubMed Web of Science ®Google Scholar
• Li W, Wang H, Yang Y, et al. Integrative analysis of proteome and ubiquitylome reveals unique features of lysosomal and endocytic pathways in gefitinib-resistant non-small cell lung cancer cells. Proteomics. 2018;18:e1700388.
   PubMed Web of Science ®Google Scholar
• Baldassarre G, Battista S, Belletti B, et al. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. Mol Cell Biol. 2003;23:2225–2238.
   PubMed Web of Science ®Google Scholar
• Ahmed KM, Tsai CY, Lee W-H. Derepression of HMGA2 via removal of ZBRK1/BRCA1/CtIP complex enhances mammary tumorigenesis. J Biol Chem. 2010;285:4464–4471.
   PubMed Web of Science ®Google Scholar
• Turk AA, Wisinski KB. PARP inhibitors in breast cancer: bringing synthetic lethality to the bedside. Cancer. 2018;124:2498–2506.
   PubMed Web of Science ®Google Scholar
• Li H, Liu Z-Y, Wu N, et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19:107.
   PubMed Web of Science ®Google Scholar
• Benecke AG, Eilebrecht S. RNA-mediated regulation of HMGA1 function. Biomolecules. 2015;5:943–957.
   PubMed Web of Science ®Google Scholar
• Aravind L, Landsman D. AT-hook motifs identified in a wide variety of DNA-binding proteins. Nucleic Acids Res. 1998;26:4413–4421.
   PubMed Web of Science ®Google Scholar
• Rohs R, Jin X, West SM, et al. Origins of specificity in protein-DNA recognition. Annu Rev Biochem. 2010;79:233–269.
   PubMed Web of Science ®Google Scholar
• Giancotti V, Bandiera A, Ciani L, et al. High-mobility-group (HMG) proteins and histone H1 subtypes expression in normal and tumor tissues of mouse. Eur J Biochem. 1993;213:825–832.
   PubMedGoogle Scholar
• Rajski SR, Williams RM. Observations on the covalent cross-linking of the binding domain (BD) of the high mobility group I/Y (HMG I/Y) proteins to DNA by FR66979. Bioorg Med Chem. 2000;8:1331–1342.
   PubMed Web of Science ®Google Scholar
• Beckerbauer L, Tepe JJ, Cullison J, et al. FR900482 class of anti-tumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo. Chem Biol. 2000;7:805–812.
   PubMed Web of Science ®Google Scholar
• Beckerbauer L, Tepe JJ, Eastman RA, et al. Differential effects of FR900482 and FK317 on apoptosis, IL-2 gene expression, and induction of vascular leak syndrome. Chem Biol. 2002;9:427–441.
   PubMedGoogle Scholar
• FK 317 - AdisInsight [Internet]. [ cited 2020 Apr 20]. Available from: https://adisinsight.springer.com/drugs/800009063.
   Google Scholar
• Cai X, Gray PJ, Von Hoff DD. DNA minor groove binders: back in the groove. Cancer Treat Rev. 2009;35:437–450.
   PubMed Web of Science ®Google Scholar
• Wegner M, Grummt F. Netropsin, distamycin and berenil interact differentially with a high-affinity binding site for the high mobility group protein HMG-I. Biochem Biophys Res Commun. 1990;166:1110–1117.
   PubMed Web of Science ®Google Scholar
• Grant MA, Baron RM, Macias AA, et al. Netropsin improves survival from endotoxaemia by disrupting HMGA1 binding to the NOS2 promoter. Biochem J. 2009;418:103–112.
   PubMed Web of Science ®Google Scholar
• Baron RM, Carvajal IM, Liu X, et al. Reduction of nitric oxide synthase 2 expression by distamycin A improves survival from endotoxemia. J Immunol. 2004;173:4147–4153.
   PubMed Web of Science ®Google Scholar
• Baron RM, Lopez-Guzman S, Riascos DF, et al. Distamycin A inhibits HMGA1-binding to the P-selectin promoter and attenuates lung and liver inflammation during murine endotoxemia. PLoS ONE. 2010;5:e10656.
   PubMed Web of Science ®Google Scholar
• Rahman A, O’Sullivan P, Rozas I. Recent developments in compounds acting in the DNA minor groove. Medchemcomm. 2019;10:26–40.
   PubMed Web of Science ®Google Scholar
• Pjura PE, Grzeskowiak K, Dickerson RE. Binding of Hoechst 33258 to the minor groove of B-DNA. J Mol Biol. 1987;197:257–271.
   PubMed Web of Science ®Google Scholar
• Radic MZ, Saghbini M, Elton TS, et al. Hoechst 33258, distamycin A, and high mobility group protein I (HMG-I) compete for binding to mouse satellite DNA. Chromosoma. 1992;101:602–608.
   PubMed Web of Science ®Google Scholar
• Alonso N, Guillen R, Chambers JW, et al. A rapid and sensitive high-throughput screening method to identify compounds targeting protein-nucleic acids interactions. Nucleic Acids Res. 2015;43:e52.
   PubMed Web of Science ®Google Scholar
• Patel SR, Kvols LK, Rubin J, et al. Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma. Invest New Drugs. 1991;9:53–57.
   PubMed Web of Science ®Google Scholar
• D’Angelo D, Borbone E, Palmieri D, et al. The impairment of the High Mobility Group A (HMGA) protein function contributes to the anticancer activity of trabectedin. Eur J Cancer. 2013;49:1142–1151.
   PubMed Web of Science ®Google Scholar
• Loria R, Laquintana V, Bon G, et al. HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance. Oncogene. 2018;37:5926–5938.
   PubMed Web of Science ®Google Scholar
• D’Incalci M, Badri N, Galmarini CM, et al. Trabectedin, a drug acting on both cancer cells and the tumour microenvironment. Br J Cancer. 2014;111:646–650.
   PubMed Web of Science ®Google Scholar
• D’Incalci M, Zambelli A. Trabectedin for the treatment of breast cancer. Expert Opin Investig Drugs. 2016;25:105–115.
   PubMed Web of Science ®Google Scholar
• Monk BJ, Lorusso D, Italiano A, et al. Trabectedin as a chemotherapy option for patients with BRCA deficiency. Cancer Treat Rev. 2016;50:175–182.
   PubMed Web of Science ®Google Scholar
• Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Annu Rev Med. 2005;56:555–583.
   PubMed Web of Science ®Google Scholar
• Camorani S, Fedele M, Zannetti A, et al. TNBC challenge: Oligonucleotide aptamers for new imaging and therapy modalities. Pharmaceuticals (Basel). 2018;11:123.
   PubMedGoogle Scholar
• Watanabe M, Sheriff S, Lewis KB, et al. HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines. Cancer Lett. 2012;315:18–27.
   PubMed Web of Science ®Google Scholar
• Hassan F, Ni S, Arnett TC, et al. Adenovirus-mediated delivery of decoy hyper binding sites targeting Oncogenic HMGA1 reduces pancreatic and liver cancer cell viability. Mol Ther Oncolytics. 2018;8:52–61.
   PubMed Web of Science ®Google Scholar
• Hassan F, Lossie SL, Kasik EP, et al. A mouse model study of toxicity and biodistribution of a replication defective adenovirus serotype 5 virus with its genome engineered to contain a decoy hyper binding site to sequester and suppress oncogenic HMGA1 as a new cancer treatment therapy. PLoS ONE. 2018;13:e0192882.
   PubMed Web of Science ®Google Scholar
• Kennedy MA Use of HGMA-targeted phosphorothioate DNA aptamers to suppress carcinogenic activity and increase sensitivity to chemotherapy agents in human cancer cells [Internet]. 2016 [ cited 2020 Apr 20]. Available from: https://patents.google.com/patent/US9233119/en.
   Google Scholar
• Nalini V, Deepa PR, Raguraman R, et al. Targeting HMGA2 in retinoblastoma cells in vitro using the aptamer strategy. Ocul Oncol Pathol. 2016;2:262–269.
   PubMed Web of Science ®Google Scholar
• Helmling S, Maasch C, Eulberg D, et al. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc Natl Acad Sci USA. 2004;101:13174–13179.
   PubMed Web of Science ®Google Scholar
• Wlotzka B, Leva S, Eschgfäller B, et al. In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc Natl Acad Sci USA. 2002;99:8898–8902.
   PubMed Web of Science ®Google Scholar
• Maasch C, Vater A, Buchner K, et al. Polyetheylenimine-polyplexes of Spiegelmer NOX-A50 directed against intracellular high mobility group protein A1 (HMGA1) reduce tumor growth in vivo. J Biol Chem. 2010;285:40012–40018.
   PubMed Web of Science ®Google Scholar
• Eilebrecht S, Brysbaert G, Wegert T, et al. 7SK small nuclear RNA directly affects HMGA1 function in transcription regulation. Nucleic Acids Res. 2011;39:2057–2072.
   PubMed Web of Science ®Google Scholar
• Akhter MZ, Sharma A, Rajeswari MR. Interaction of adriamycin with a promoter region of hmga1 and its inhibitory effect on HMGA1 expression in A431 human squamous carcinoma cell line. Mol Biosyst. 2011;7:1336–1346.
   PubMedGoogle Scholar
• Karp JE, Smith BD, Resar LS, et al. Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 2011;117:3302–3310.
   PubMed Web of Science ®Google Scholar
• Nelson DM, Joseph B, Hillion J, et al. Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma. 2011;52:1999–2006.
   PubMed Web of Science ®Google Scholar
• Song X, Liu W, Xie S, et al. All-transretinoic acid ameliorates bleomycin-induced lung fibrosis by downregulating the TGF-β1/Smad3 signaling pathway in rats. Lab Invest. 2013;93:1219–1231.
   PubMed Web of Science ®Google Scholar
• Roush S, Slack FJ. The let-7 family of microRNAs. Trends Cell Biol. 2008;18:505–516.
   PubMed Web of Science ®Google Scholar
• Yu F, Yao H, Zhu P, et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell. 2007;131:1109–1123.
   PubMed Web of Science ®Google Scholar
• Pollak M. Potential applications for biguanides in oncology. J Clin Invest. 2013;123:3693–3700.
   PubMed Web of Science ®Google Scholar
• Yan L, Zhou J, Gao Y, et al. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene. 2015;34:3076–3084.
   PubMed Web of Science ®Google Scholar
• Xia C, Liang S, He Z, et al. Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells. Eur J Pharmacol. 2018;830:59–67.
   PubMed Web of Science ®Google Scholar
• Di Fazio P, Montalbano R, Neureiter D, et al. Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines. Exp Cell Res. 2012;318:1832–1843.
   PubMed Web of Science ®Google Scholar
• Harada-Shirado K, Ikeda K, Ogawa K, et al. Dysregulation of the MIRLET7/HMGA2 axis with methylation of the CDKN2A promoter in myeloproliferative neoplasms. Br J Haematol. 2015;168:338–349.
   PubMed Web of Science ®Google Scholar
• Ruscetti M, Dadashian EL, Guo W, et al. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer. Oncogene. 2016;35:3781–3795.
   PubMed Web of Science ®Google Scholar
• Li Y, Pi X-Y, Boland K, et al. Hmga2 translocation induced in skin tumorigenesis. Oncotarget. 2017;8:30019–30029.
   PubMedGoogle Scholar
• Lee S, Jung J-W, Park S-B, et al. Histone deacetylase regulates high mobility group A2-targeting microRNAs in human cord blood-derived multipotent stem cell aging. Cell Mol Life Sci. 2011;68:325–336.
   PubMed Web of Science ®Google Scholar
• Sahai V, Kumar K, Knab LM, et al. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen. Mol Cancer Ther. 2014;13:1907–1917.
   PubMed Web of Science ®Google Scholar
• Kitchen MO, Yacqub-Usman K, Emes RD, et al. Epidrug mediated re-expression of miRNA targeting the HMGA transcripts in pituitary cells. Pituitary. 2015;18:674–684.
   PubMed Web of Science ®Google Scholar
• Yamada S, Tsukamoto S, Huang Y, et al. Epigallocatechin-3-O-gallate up-regulates microRNA-let-7b expression by activating 67-kDa laminin receptor signaling in melanoma cells. Sci Rep. 2016;6:19225.
   PubMed Web of Science ®Google Scholar
• Wu Z, Eguchi-Ishimae M, Yagi C, et al. HMGA2 as a potential molecular target in KMT2A-AFF1-positive infant acute lymphoblastic leukaemia. Br J Haematol. 2015;171:818–829.
   PubMed Web of Science ®Google Scholar
• Cinkornpumin J, Roos M, Nguyen L, et al. A small molecule screen to identify regulators of let-7 targets. Sci Rep. 2017;7:15973.
   PubMed Web of Science ®Google Scholar
• Liu K, Zhang C, Li T, et al. Let-7a inhibits growth and migration of breast cancer cells by targeting HMGA1. Int J Oncol. 2015;46:2526–2534.
   PubMed Web of Science ®Google Scholar
• Berlingieri MT, Pierantoni GM, Giancotti V, et al. Thyroid cell transformation requires the expression of the HMGA1 proteins. Oncogene. 2002;21:2971–2980.
   PubMed Web of Science ®Google Scholar
• De Martino M, Fusco A, Esposito F. HMGA and cancer: a review on patent literatures. Recent Pat Anticancer Drug Discov. 2019;14:258–267.
   PubMed Web of Science ®Google Scholar
• Resar LMS, Huso D, Cope L Methods of inhibiting cancer stem cells with HMGA1 inhibitors [Internet]. 2017 [ cited 2020 Apr 20]. Available from: https://patents.google.com/patent/US9545417B2/en.
   Google Scholar
• Seifi-Najmi M, Hajivalili M, Safaralizadeh R, et al. SiRNA/DOX lodeded chitosan based nanoparticles: development, characterization and in vitro evaluation on A549 lung cancer cell line. Cell Mol Biol (Noisy-le-grand). 2016;62:87–94.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Wang Y. HMG modifications and nuclear function. Biochim Biophys Acta. 2010;1799:28–36.
   PubMed Web of Science ®Google Scholar
• Mansoori B, Mohammadi A, Shirjang S, et al. HMGI-C suppressing induces P53/caspase9 axis to regulate apoptosis in breast adenocarcinoma cells. Cell Cycle. 2016;15:2585–2592.
   PubMed Web of Science ®Google Scholar
• Perini GF, Ribeiro GN, Pinto Neto JV, et al. BCL-2 as therapeutic target for hematological malignancies. J Hematol Oncol. 2018;11:65.
   PubMed Web of Science ®Google Scholar
• Deeks ED. Venetoclax: first global approval. Drugs. 2016;76:979–987.
   PubMed Web of Science ®Google Scholar
• Cha YH, Kim NH, Park C, et al. MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling. Cell Cycle. 2012;11:1273–1281.
   PubMed Web of Science ®Google Scholar
• Bonetti P, Climent M, Panebianco F, et al. Dual role for miR-34a in the control of early progenitor proliferation and commitment in the mammary gland and in breast cancer. Oncogene. 2019;38:360–374.
   PubMed Web of Science ®Google Scholar
• Resmini G, Rizzo S, Franchin C, et al. HMGA1 regulates the Plasminogen activation system in the secretome of breast cancer cells. Sci Rep. 2017;7:11768.
   PubMed Web of Science ®Google Scholar
• Duffy MJ, McGowan PM, Harbeck N, et al. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res. 2014;16:428.
   PubMed Web of Science ®Google Scholar
• Tang L, Han X. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed Pharmacother. 2013;67:179–182.
   PubMed Web of Science ®Google Scholar
• Schmitt M, Harbeck N, Brünner N, et al. Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Rev Mol Diagn. 2011;11:617–634.
   PubMed Web of Science ®Google Scholar
• Linderholm BK, Hellborg H, Johansson U, et al. Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol. 2009;20:1639–1646.
   PubMed Web of Science ®Google Scholar
• Li Q, Yan H, Zhao P, et al. Efficacy and safety of Bevacizumab combined with chemotherapy for managing metastatic breast cancer: a meta-analysis of randomized controlled trials. Sci Rep. 2015;5:15746.
   PubMed Web of Science ®Google Scholar
• Pegoraro S, Ros G, Ciani Y, et al. A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness. Oncotarget. 2015;6:19087–19101.
   PubMedGoogle Scholar
• Sánchez-Martínez C, Lallena MJ, Sanfeliciano SG, et al. Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: recent advances (2015-2019). Bioorg Med Chem Lett. 2019;29:126637.
   PubMed Web of Science ®Google Scholar
• Caldon CE, Sergio CM, Burgess A, et al. Cyclin E2 induces genomic instability by mechanisms distinct from cyclin E1. Cell Cycle. 2013;12:606–617.
   PubMed Web of Science ®Google Scholar
• Thomas AL, Lind H, Hong A, et al. Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells. Cell Cycle. 2017;16:1453–1464.
   PubMed Web of Science ®Google Scholar
• Chirshev E, Oberg KC, Ioffe YJ, et al. Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer. Clin Transl Med. 2019;8:24.
   PubMed Web of Science ®Google Scholar
• Balzeau J, Menezes MR, Cao S, et al. The LIN28/let-7 pathway in cancer. Front Genet. 2017;8:31.
   PubMed Web of Science ®Google Scholar
• Malini E, Maurizio E, Bembich S, et al. HMGA interactome: new insights from phage display technology. Biochemistry. 2011;50:3462–3468.
   PubMed Web of Science ®Google Scholar
• Tsafou K, Tiwari PB, Forman-Kay JD, et al. Targeting intrinsically disordered transcription factors: changing the paradigm. J Mol Biol. 2018;430:2321–2341.
   PubMed Web of Science ®Google Scholar
• Santofimia-Castaño P, Rizzuti B, Xia Y, et al. Targeting intrinsically disordered proteins involved in cancer. Cell Mol Life Sci. 2019;77:1695–1707.
   PubMed Web of Science ®Google Scholar
• Heller GT, Aprile FA, Vendruscolo M. Methods of probing the interactions between small molecules and disordered proteins. Cell Mol Life Sci. 2017;74:3225–3243.
   PubMed Web of Science ®Google Scholar
• Uversky VN. New technologies to analyse protein function: an intrinsic disorder perspective. F1000Res. 2020;9:101.
   Google Scholar
• Boeynaems S, Alberti S, Fawzi NL, et al. Protein phase separation: a new phase in cell biology. Trends Cell Biol. 2018;28:420–435.
   PubMed Web of Science ®Google Scholar
• Uversky VN. Supramolecular fuzziness of intracellular liquid droplets: liquid-liquid phase transitions, membrane-less organelles, and intrinsic disorder. Molecules. 2019;24:3265.
   PubMed Web of Science ®Google Scholar
• Alberti S, Dormann D. Liquid-liquid phase separation in disease. Annu Rev Genet. 2019;53:171–194.
   PubMed Web of Science ®Google Scholar